Australian Government

Department of Health and Aged Care

Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:	377474 APRETUDE cabotegravir 600 mg/3 mL prolonged-release suspension for injection vial
ARTG entry for	Medicine Registered
Sponsor	ViiV Healthcare Pty Ltd
Postal Address	PO Box 18095, MELBOURNE CITY MC, VIC, 8001 Australia
ARTG Start Date	11/08/2022
Product Category	Medicine
Status	Active
Approval Area	Drug Safety Evaluation Branch

Medicine under additional monitoring

Conditions

Conditions applicable to the relevant category and class of therapeutic goods as specified in the document "Conditions Applying to Therapeutic Goods Accepted for Registration or Listing as Goods Currently Supplied at the Commencement of the Therapeutic Goods Act 1989"

Conditions applicable to all therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 February 1992, other than condition No. 8 and condition No. 9.

Conditions applicable to the relevant category and class of therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 February 1992, other than condition No. 11.

Except where the sponsor has been contracted by an overseas partry to manufacturer the goods and that party will be responsible for placing the goods on the market in countries other than Australia, the sponsor must have and shall retain, while the goods remain listed, evidence necessary to substantiate and support the accuracy of the indications in relation to the listed goods, and upon the request of the Head, Office of Prescription Medicines Authorisation Branch, Therapeutic Goods Administration, shall produce such evidence to this officer.

The conditions applying to these goods when they are exported from Australia are given below:

Conditions applicable to all therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995, other than condition No. 8 and condition No. 9.

Conditions applicable to the relevant category and class of therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995, other than condition No.11

Conditions applicable to all therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995.

Conditions applicable to the relevant category and class of therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995.

The therapeutic goods grouped in this registration/listing as export only goods under the following names are included in the Australian Register of Therapeutic Goods and may not be supplied in Australia. Export Name(s) to be added:

Products

1 . APRETUDE cabotegravir 600 mg/3 mL prolonged-release suspension for injection vial

Product Type	Single Medicine Product	**Effective Date**	18/09/2023

Permitted Indications

No Permitted Indications included on Record

Indication Requirements

No Indication Requirements included on Record

Standard Indications

No Standard Indications included on Record

Specific Indications

APRETUDE is indicated in at-risk adults and adolescents (at least 12 years of age) and weighing at least 35 kg for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection.,APRETUDE tablets may be used as an oral lead-in to assess tolerability of cabotegravir prior to administration of cabotegravir injections or as short-term oral PrEP in individuals who will miss planned dosing with cabotegravir injections.,Individuals must have a documented negative HIV-1 test prior to initiating APRETUDE for HIV-1 PrEP.

Warnings

See Product Information and Consumer Medicine Information for this product

Additional Product information

This product is included in the Black Triangle Scheme

Container information

Type	Material	Life Time	Temperature	Closure	Conditions
Vial	Glass Type I Clear	36 Months	Store below 30 degrees Celsius	Not recorded	Do not Freeze

Pack Size/Poison information

Pack Size	Poison Schedule
1 vial 600 mg/3 mL cabotegravir	(S4) Prescription Only Medicine
25 x 1 vial 600 mg/3 mL cabotegravir	(S4) Prescription Only Medicine

Components

1 . APRETUDE cabotegravir 600 mg/3 mL prolonged-release suspension for injection vial

Dosage Form	Injection, suspension
Route of Administration	Intramuscular
Visual Identification	white to light pink suspension

Active Ingredients

cabotegravir	**600 mg**

Other Ingredients (Excipients)

macrogol 3350
mannitol
polysorbate 20
water for injections

Public Summary